🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "huge turning point" in the battle against superbug strains of the pathogen, according to health experts.

A Global Health Concern

The sexually transmitted infection are increasing globally, with estimates suggesting over 82 million instances per year. Particularly high rates are seen in Africa and nations within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary advancement in the reality of rising global incidence, increasing antimicrobial resistance and the highly restricted treatment choices at this time.”

Public health authorities are increasingly worried about the surge in treatment-resistant strains. The WHO has classified it as a "high-priority threat". Recent surveillance revealed that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Treatment Options Receive Clearance

Zoliflodacin, also known as Nuzolvence, was cleared by the US FDA in mid-December for combating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Experts hope that focused deployment of this new drug will help hinder the emergence of superbugs.

Gepotidacin, created by the drugmaker GSK, was also approved in the same week. This treatment, which is employed against urinary tract infections, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin stemmed from a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to see it through.

“This authorization signifies a major breakthrough in the management of multidrug-resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Research Study Data and Global Access

Based on results released by a prominent scientific publication, zoliflodacin successfully treated more than 90% of genital gonorrhoea infections. This places it at an equal footing with the existing first-line therapy, which involves two antibiotics. The research involved nearly 1,000 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the rights to license and sell the drug in many developing nations.

Clinicians directly involved have expressed optimism. Having a single-dose, oral treatment of this kind is described as a "game-changer" for managing the epidemic. This is viewed as vital to alleviate the strain of the infection for patients and to prevent the spread of untreatable gonorrhoea globally.